



RYDAPT (midostaurin)

Instructions

Please complete Part A and have your physician complete Part B. This form may not apply to your specific plan. Before completing the Prior Authorization form, check that this medication is on your plan's drug coverage list. Completion and submission is not a guarantee of approval. Any fees related to the completion of this form are the responsibility of the plan member. Drugs in the Prior Authorization Program may be eligible for reimbursement if the patient does not qualify for coverage under a primary plan or a government program. Drugs used for indications not approved by Health Canada may be denied. For Quebec plan members, RAMQ exception drug criteria may apply. The decision for approval versus denial is based on pre-defined clinical criteria, primarily based on Health Canada approved indication(s) and on supporting evidence-based clinical protocols. The plan member will be notified whether their request has been approved or denied. If you've already purchased the drug, please attach your original receipts along with a regular extended health care claim form.

<u>Part A – Patient</u> Patient Information

ratient informatio	<u> </u>			
First Name:			Last Name:	
Insurance Carrier N	lame/Number:		,	
Group Number:			Client ID:	
Date of Birth (YYYY,	/MM/DD):		Relationship: Em	nployee Spouse Dependent
Language: Eng	glish French		Gender: Male	Female
Address:				
City:		Province:		Postal Code:
Email address:				
Telephone (home):		Telephone (cell):		Telephone (work):
The patient is a	ox that applies to the pat in over-age student depe tional institution confirm	endent (i.e. attending		ull-time). A copy of the enrolment document
The patient is a		over age 18. The patie	ent has signed the auth	norization section below that allows Sun Life
Coordination of be	enefits			
Provincial Coverage				. To find out if you qualify for coverage, I response letter to your pharmacist when
Primary Coverage	Has the patient applied What is the coverage d		inder a primary plan?	Yes No N/A





RYDAPT (midostaurin)

Authorization

The answers on this form are true. I allow Sun Life to collect, use and disclose my personal information for three reasons. These reasons are plan administration, underwriting coverage and assessing claims. Sun Life may share (meaning collect and disclose) information with healthcare providers, hospitals, clinics, pharmacies, government programs, patient assistance programs, and any other organization with relevant information about me. Sun Life may also share information with insurers or reinsurers, and agents and service providers of Sun Life and the above parties. Sun Life will share my information only when necessary. My consent applies while this plan is in effect.

I agree that a photocopy or electronic version of this authorization is as valid as the original.

Plan Member Signature	Date
Patient Signature (if over 18 years of age)	- Date





RYDAPT (midostaurin)

Part B - Prescriber

SECTION 1 - DRUG REQUESTED

Please see instructions on page 1 and complete all sections below. <u>Incomplete forms may result in automatic denial</u>. Please do **not** provide genetic test information or results.

RYDAPT (midostauri	n)	☐ New	request Rene	ewal request*
DIN(s)	Dose	Administration (ex: oral, IV, etc)	Frequency	Duration
Site of drug administrat	ion:			
	ician's office/Private Clin	ic Private Clinic (within F	Hospital - no public or gov	vernment funding)
Hospital (inpatient)	Hospital (outpati	ient)		
Name of the hospital or	private clinic:			
Address:				
City:	Prov	rince:	Postal code:	
* Diago submit proof	of prior coverage if avail	abla		
^ Please Submit proof	or prior coverage if avail	able		
SECTION 2 - ELIGIBI	LITY CRITERIA			
1. Please indicate if the	ne patient satisfies the b	elow criteria:		
Acute Myeloid Leukemi	a			
For the treatme	ent of acute myeloid leuk	emia with FLT3 mutation in an ac	dult, AND	
The patient is r	newly diagnosed or has n	ot received prior therapy, AND		
The patient is r	not a candidate for stand	ard induction and consolidation of	chemotherapy, AND	
RYDAPT will be	used in combination wit	h standard cytarabine and dauno	rubicin induction, OR	
RYDAPT will be	used in combination wit	h standard cytarabine consolidati	ion	
Systemic Mastocytosis	– Aggressive			
For the treatme	ent of aggressive system	ic mastocytosis (ASM) in an adult		
Systemic Mastocytosis	 Associated Hematolog 	ical Neoplasm		
For the treatme	ent of systemic mastocyt	osis with associated hematologic	al neoplasm (SM-AHN) in	an adult
Mast Cell Leukemia For the treatme	ent of mast cell leukemia	ı (MCL) in an adult		





RYDAPT (midostaurin)

OR None of the choice evitoric applies	
None of the above criteria applies.	
Relevant additional information:	
SECTION 3 - PRESCRIBER INFORMATION	
Physician's Name:	
Address:	
	_
Tel:	Fax:
License No.:	Specialty:
Physician Signature:	Date:

SECTION 4 - RESPECTING YOUR PRIVACY

Our Purpose is to help our Clients achieve lifetime financial security and live healthier lives. We collect, use and disclose your personal information to: develop and deliver the right products and services; enhance your experience and manage our business operations; perform underwriting, administration and claims adjudication; protect against fraud, errors or misrepresentations; tell you about other products and services; and meet legal and security obligations. We collect it directly from you, when you use our products and services, and from other sources. We keep your information confidential and only as long as needed. People who may access it include our employees, distribution partners such as advisors, service providers, reinsurers, or anyone else you authorize. At times, unless we're prohibited, they may be outside your jurisdiction and your information may be subject to local laws. You can always ask for your information and to correct it if needed. In most cases, you have a right to withdraw your consent, but we may not be able to provide the requested product or service. Read our Global Privacy Statement and local policy at www.sunlife.ca/privacy or call us for a copy.

Questions? Please visit www.sunlife.ca or call toll-free 1-800-361-6212 Monday - Friday, 8 a.m. - 8 p.m. ET





RYDAPT (midostaurin)

SECTION 5 - CONTACT US

reference number.

OR

Please fax or mail the completed form to Sun Life Assurance Company of Canada ${\mathbb R}$

FAX: 1-855-342-9915 Mail:

Sun Life Assurance Company of

Canada

Attention: Claims Dept. PO Box 11658 STN CV Montreal, QC H3C 6C1 Sun Life Assurance Company of

Canada

Attention: Claims Dept.
PO Box 2010 STN Waterloo
Waterloo, ON N2J 0A6